Research Coverage


Code: 4548Last Update:
Research Reports
Download Research Report

Seikagaku develops new drugs in-house, conducts clinical trials, and submits applications for approval from regulatory authorities such as the Ministry of Health, Labour and Welfare (Japan) and the FDA (US). It manufactures drugs itself, but sells through pharmaceutical companies of sales partner that are strong in specific areas. Earnings are driven by GPM of products sold to sales partners. Since its establishment in 1947, it has specialized in glycoscience (study of sugar chains and glycoconjugates), developing and manufacturing related drugs and bulk drugs.

Our Policy

We interview management for hours, asking exhaustive questions to uncover the essence of the business.

We pinpoint strengths and weaknesses, and discuss strategy. Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue.

Our Research

We start our coverage with a substantial core report. We then continuously update this report to reflect earnings, newsflow, and any material developments. We interview the management quarterly to help you stay on top of the story.

Our report is an authoritative Owner’s Manual of the company—a vital piece in the investor’s toolbox.

For Investors

If you find our efforts valuable, please tell companies you want them to join our growing client list.